News for uniQure N.V. (QURE)

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

**media[643746]**

~ No serious adverse events and 92% reduction in seizure frequency observed in the first trial participant through first five months of follow up ~ ~ Data to

**media[640256]**

uniQure divested for $25M, advanced AMT-130 with FDA approvals, and building infrastructure. A strong balance sheet backs AMT-130’s BLA. See more on QURE here.

NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. ( CRBP), a clinical-stage company focused on oncology and obesity, today

uniQure N.V. (NASDAQ:QURE) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ETCompany ParticipantsChiara Russo - Senior Director, Investor RelationsMatt...

~ AMT-130 granted Breakthrough Therapy designation by FDA ~ ~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generall

**media[620252]**

~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 05, 2025 (GLOBE NEWS

U.S. stocks were lower, with the Dow Jones index falling around 700 points on Monday. Shares of Wolverine World Wide, Inc. WWW rose sharply during Monday's ses...

U.S. stocks were lower, with the Dow Jones index falling around 550 points on Thursday. Shares of uniQure N.V. QURE rose sharply during Thursday's session afte...

Key Highlights: uniQure (QURE) revenue and earnings per share fell short of analyst expectations. The company's projected revenue growth outpaces the ind

~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~ ~ Additional regulator

uniQure (QURE) receives FDA Breakthrough Therapy designation for AMT-130, potentially accelerating regulatory approval for Huntington's disease treatment

**media[597939]**

uniQure (QURE) delivered earnings and revenue surprises of -240.91% and 85.71%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

~ Announced alignment with the U.S. Food and Drug Administration (FDA) on key elements of the Accelerated Approval pathway for AMT-130 in Huntington's disease;

**media[552098]**